Acadia Pharma (ACAD) Misses Q1 EPS by 10c; Offers FY22 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall St set for higher open as AI stocks rise, oil slides
- Streamflation drives 39% of Americans to cancel streaming in 6 months
Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results
May 4, 2022 4:05 PM EDT- 1Q22 net sales of $115.5 million, an 8% increase over 1Q21
- Reiterating FY22 net sales guidance of $510 to $560 million
- FDA Advisory Committee meeting to review sNDA for pimavanserin for the treatment of ADP scheduled for June 17, 2022
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2022.
NUPLAZID continued to deliver year over year growth in the first quarter of 2022, said Steve Davis, Chief Executive Officer. In the near... More
